Craig-Hallum analyst Kevin Ellich raised his price target for Henry Schein to $77 from $72 after the company reported "solid" Q1 results and 2019 EPS guidance was raised at the upper end of the range. The analyst is encouraged by the "solid" Q1 results following the animal health spinoff in February and remains optimistic about the remainder of this year as management continues to focus on strategic growth initiatives such as shifting to higher margin products in dental and medical, as well as delivering on cost initiatives and expansion outside of the U.S. Ellich reiterates a Buy rating on the shares.